Skip to main content
. Author manuscript; available in PMC: 2015 Feb 1.
Published in final edited form as: Nanomedicine. 2013 Aug 3;10(2):359–369. doi: 10.1016/j.nano.2013.07.014

Figure 6.

Figure 6

Examining the efficacy of DNR and ND-R by measuring the cellular viability of K562 and K562/DNR after exposure to range of drug concentrations. (A) A summary of the IC-50, or half maximal inhibitory concentrations of DNR and ND-R treatments. ND-R exhibited improved efficacy towards treating resistant K562 as compared with DNR. The resistance of K562/DNR is confirmed by the 4 fold increase over K562 in IC-50 value when exposed to DNR. **p < 0.5 (B) K562 + DNR (avg. r2 = 0.97) (C) K562/DNR + DNR (avg. r2 = 0.96) (D) K562 + ND-R (avg. r2 = 0.94) (E) K562/DNR + ND-R (avg. r2 = 0.96) dose response curves fitted to a sigmoid function. Each graph contains three trials with separate sigmoidal curves fitted to each trial. Mean IC-50 values are averaged over these three trials.